A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Mati Therapeutics Inc.

Overview

The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Glaucoma Ocular Hypertension

Interventions

Latanoprost-PPDSDRUG

Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Over 18 yrs of age with ocular hypertension or open-angle glaucoma * Subjects who have a best corrected visual acuity of 20/100 or better Exclusion Criteria: * Subjects who wear contact lenses. * Uncontrolled medical conditions * Subjects requiring chronic topical artifical tears, lubricants and/or requiring any other chronic topical medications * Subjects who have a history of chronic or recurrent inflammatory eye disease

Outcomes

Primary Outcomes

IOP change from baseline

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.